We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Spectrum (SPPI) Reports Narrower-than-Expected Q3 Loss
Read MoreHide Full Article
Spectrum Pharmaceuticals, Inc. reported a loss of 22 cents per share in the third quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 32 cents. Adjusted loss (including stock-based compensation expense) in the quarter came in at 11 cents per share.
Quarterly revenues came in at $33.4 million for the third quarter of 2016, up 16.8% from the year-ago quarter and above the Zacks Consensus Estimate of $30 million.
Quarter in Detail
Spectrum Pharma earns revenues from six marketed products – Fusilev, Folotyn, Zevalin, Marqibo, Beleodaq and Evomela. Total product sales came in at $30.3 million, up 6.3% year over year.
Fusilev sales came in at $4.9 million, down 55.9%, while Folotyn sales were up 29.9% to $11.3 million. Beleodaq generated sales of 3.6 million, up 38.5%, while Marqibo sales were up 46.2% to $1.9 million. However, Zevalin sales plunged 45.8% to $2.6 million. Lastly, Evomela raked in sales of $5.9 million.
License fees and service revenues came in at $3.1 million.
Research & development expenses were $13.3 million, up 34.3%, while selling, general and administrative spending inched up 0.5% to $19.5 million.
Pipeline Update
Spectrum Pharma has been making progress on the development of its pipeline candidates. The company is currently enrolling patients in a phase III study on Rolontis (SPI-2012), under a Special Protocol Assessment (SPA) agreement from the FDA, for the treatment of chemotherapy-induced neutropenia in patients with breast cancer. A biologics license application (BLA) is expected to be filled in 2018.
In addition, the company is evaluating poziotinib in a phase II study for the treatment of breast cancer in patients who have failed multiple other HER2-directed therapies.
Our Take
Spectrum Pharma’s third-quarter results were encouraging, with a narrower-than-expected loss and better-than-anticipated revenues. However, we remain concerned about the declining product sales at the company. Fusilev sales may continue to tumble in the upcoming quarters due to stiff competition in this space.
Going forward, we expect investors to remain focused further on updates by the company.
Spectrum Pharma currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Anika Therapeutics Inc. (ANIK - Free Report) , Cambrex Corp. and Vanda Pharmaceuticals, Inc. (VNDA - Free Report) . Each of these stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika’s earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company has posted a positive surprise in all of the four trailing quarters with an average beat of 33.14%.
Vanda’s loss estimates narrowed from 68 cents to 56 cents for 2016 over the last 60 days, while its earnings estimates have increased from 16 cents to 17 cents for 2017. The company has posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%.
Cambrex’s earnings estimates have increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company has posted a positive earnings surprise in three of the trailing four quarters with an average beat of 19.78%.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Spectrum (SPPI) Reports Narrower-than-Expected Q3 Loss
Spectrum Pharmaceuticals, Inc. reported a loss of 22 cents per share in the third quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 32 cents. Adjusted loss (including stock-based compensation expense) in the quarter came in at 11 cents per share.
Quarterly revenues came in at $33.4 million for the third quarter of 2016, up 16.8% from the year-ago quarter and above the Zacks Consensus Estimate of $30 million.
Quarter in Detail
Spectrum Pharma earns revenues from six marketed products – Fusilev, Folotyn, Zevalin, Marqibo, Beleodaq and Evomela. Total product sales came in at $30.3 million, up 6.3% year over year.
Fusilev sales came in at $4.9 million, down 55.9%, while Folotyn sales were up 29.9% to $11.3 million. Beleodaq generated sales of 3.6 million, up 38.5%, while Marqibo sales were up 46.2% to $1.9 million. However, Zevalin sales plunged 45.8% to $2.6 million. Lastly, Evomela raked in sales of $5.9 million.
License fees and service revenues came in at $3.1 million.
Research & development expenses were $13.3 million, up 34.3%, while selling, general and administrative spending inched up 0.5% to $19.5 million.
Pipeline Update
Spectrum Pharma has been making progress on the development of its pipeline candidates. The company is currently enrolling patients in a phase III study on Rolontis (SPI-2012), under a Special Protocol Assessment (SPA) agreement from the FDA, for the treatment of chemotherapy-induced neutropenia in patients with breast cancer. A biologics license application (BLA) is expected to be filled in 2018.
In addition, the company is evaluating poziotinib in a phase II study for the treatment of breast cancer in patients who have failed multiple other HER2-directed therapies.
Our Take
Spectrum Pharma’s third-quarter results were encouraging, with a narrower-than-expected loss and better-than-anticipated revenues. However, we remain concerned about the declining product sales at the company. Fusilev sales may continue to tumble in the upcoming quarters due to stiff competition in this space.
Going forward, we expect investors to remain focused further on updates by the company.
SPECTRUM PHARMA Price, Consensus and EPS Surprise
SPECTRUM PHARMA Price, Consensus and EPS Surprise | SPECTRUM PHARMA Quote
Zacks Rank & Key Picks
Spectrum Pharma currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Anika Therapeutics Inc. (ANIK - Free Report) , Cambrex Corp. and Vanda Pharmaceuticals, Inc. (VNDA - Free Report) . Each of these stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika’s earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company has posted a positive surprise in all of the four trailing quarters with an average beat of 33.14%.
Vanda’s loss estimates narrowed from 68 cents to 56 cents for 2016 over the last 60 days, while its earnings estimates have increased from 16 cents to 17 cents for 2017. The company has posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%.
Cambrex’s earnings estimates have increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company has posted a positive earnings surprise in three of the trailing four quarters with an average beat of 19.78%.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>